Breaking News
December 12, 2017 - Novel approach could limit common complications of immunotherapy
December 12, 2017 - CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patients
December 12, 2017 - Live-cell microscopy reveals internal forces that direct cell migration
December 12, 2017 - GSK Submits US Regulatory Application for Single-Dose Tafenoquine for Plasmodium vivax Malaria
December 12, 2017 - High Blood Urea Nitrogen Levels Tied to T2D Risk
December 12, 2017 - Blood Smear: MedlinePlus Lab Test Information
December 12, 2017 - Atopic eczema—one size does not fit all
December 12, 2017 - Biological Applications of AFM
December 12, 2017 - Genentech researchers uncover epigenetic regulator of pancreatic cancer cells
December 12, 2017 - Study provides new insights into mechanism of tumor survival in glioblastoma
December 12, 2017 - FDA Approves Admelog (insulin lispro) Short-Acting “Follow-On” Insulin Product to Treat Diabetes
December 12, 2017 - Chromosomes Fact Sheet – National Human Genome Research Institute (NHGRI)
December 12, 2017 - Discovery puts the brakes on HIV’s ability to infect
December 12, 2017 - Researchers uncover novel strategy to program immune system for fighting cancer
December 12, 2017 - Study finds under-age marriage for women as marker of multiple vulnerabilities
December 12, 2017 - Scientists discover specific mechanism of Zika virus-associated microcephaly
December 12, 2017 - Creating Your Family Health Tree
December 12, 2017 - Biological Pathways Fact Sheet – National Human Genome Research Institute (NHGRI)
December 12, 2017 - LSUHealthNO breakthrough may pave way for advances in obesity-related diseases
December 12, 2017 - Few people with HIV get prompt care after incarceration
December 11, 2017 - Air pollution exposure before or after conception linked to increased risk of birth defects in children
December 11, 2017 - Abu Dhabi focuses on reducing childhood obesity
December 11, 2017 - Employees with influenza have more lost work time
December 11, 2017 - type 2 diabetes – Genetics Home Reference
December 11, 2017 - Insufficient evidence to guide recommendations on vitamin D in pregnancy
December 11, 2017 - St. Jude gene therapy offers hope for infants with ‘bubble boy’ disease
December 11, 2017 - Soy foods, cruciferous vegetables may reduce breast cancer treatment’s side effects
December 11, 2017 - Nearly 3 in 10 elite footballers at top clubs have undetected lung and airway problems, study finds
December 11, 2017 - Why some workers can’t call it quits
December 11, 2017 - Healthier Diet, Less Salt: The Recipe to Beat High Blood Pressure: MedlinePlus Health News
December 11, 2017 - Research leads to call for lung health screening at top football clubs
December 11, 2017 - Drug improves disease-free, overall survival after hematopoietic stem cell transplants
December 11, 2017 - Researchers generate 3D cell cultures to investigate mechanisms of drug resistance in breast cancer
December 11, 2017 - New, more easily administered therapies offer benefits for bleeding and clotting disorders
December 11, 2017 - Opioids after surgery left her addicted. Is that a medical error?
December 11, 2017 - Scientists develop software that predicts leukemia-specific immune targets
December 11, 2017 - Does Your Pet Have a Weight Problem? Here’s How to Tell: MedlinePlus Health News
December 11, 2017 - Genetic variant prompts cells to store fat, fueling obesity
December 11, 2017 - Canola oil linked to worsening of Alzheimer’s
December 11, 2017 - New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too
December 11, 2017 - Healthy Living May Ease Some MS Symptoms: MedlinePlus Health News
December 11, 2017 - Researchers develop a molecular taxonomy for hair disorders
December 11, 2017 - Study shows safety, efficacy of cystic fibrosis drug in children between 1 to 2 years of age
December 11, 2017 - Two immunotherapy approaches for multiple myeloma show hope
December 11, 2017 - The Valley Hospital uses novel mobile app to enhance pre-hospital emergency care
December 11, 2017 - ‘I Entered Medical School Through a Hunger Strike’: What We Heard This Week
December 11, 2017 - Research team unlocks secrets of Ebola
December 11, 2017 - Generic versions of Viagra coming this week
December 11, 2017 - New genetic model identified for predicting outcomes in patients with primary myelofibrosis
December 11, 2017 - Research shows that e-cigarettes serve as gateway to traditional smoking
December 11, 2017 - A risk factor for drug-induced skin disease identified
December 11, 2017 - MIT researchers discover new way to make bacteria vulnerable to existing antibiotics
December 11, 2017 - Dengue vaccine issues in the Philippines
December 11, 2017 - Office Workers Don’t Like Being Chained to Their Desks: MedlinePlus Health News
December 11, 2017 - Study reveals how a very low calorie diet can reverse type 2 diabetes
December 11, 2017 - Study highlights potential for reducing greenhouse gas emissions in health care settings
December 11, 2017 - University of Adelaide receives $23.2 million for preterm birth research
December 11, 2017 - Tough Flu Season Ahead: Vaccine May Only Be 10% Effective
December 11, 2017 - Getting Self-Driving Cars on the Road Soon Might Save Lives: MedlinePlus Health News
December 11, 2017 - Enterovirus vaccine prevents virus-induced diabetes in a T1D experimental model
December 11, 2017 - Solar retinopathy or sun damage to the eyes – a case report
December 11, 2017 - Cancer risk with birth control pills emerges again in latest study
December 10, 2017 - Deer Hunters: Put Safety First: MedlinePlus Health News
December 10, 2017 - High blood pressure is redefined as 130, not 140: US guidelines (Update)
December 10, 2017 - Unusual neuroinflammation may underlie cognitive problems in cART-treated HIV patients
December 10, 2017 - Racial differences in parents’ reports of child’s autism symptoms may contribute to delayed diagnosis
December 10, 2017 - Taurine could boost effectiveness of existing multiple sclerosis therapies
December 10, 2017 - The man with a young woman’s heart
December 10, 2017 - Patient bedside remains important component of medical education for students
December 10, 2017 - Nutrition labeling has little impact on sodium consumption
December 10, 2017 - ‘Obesity paradox’ not present among people with new cases of cardiovascular disease
December 10, 2017 - SLU scientists provide promising approach in designing new drugs for DMD
December 10, 2017 - Can PD-1 Inhibitor Help Eradicate HIV?
December 10, 2017 - Checking Prices for Medical Procedures Online? Good Luck: MedlinePlus Health News
December 10, 2017 - Researchers find bacteria tied to esophageal cancer
December 10, 2017 - Boy’s Double Hand Transplant Changed His Brain
December 10, 2017 - Memo to Doctors: Spit Out the Bad News: MedlinePlus Health News
December 10, 2017 - Two years of extended anastrozole therapy proved as effective as five years in clinical trial
December 10, 2017 - Using digital devices before bed may contribute to sleep and nutrition problems in children
December 10, 2017 - Are You Sure That’s What the Doctor Said About Your Leukemia?: MedlinePlus Health News
FDA Alert: Biotin (Vitamin B7): Safety Communication

FDA Alert: Biotin (Vitamin B7): Safety Communication

image_pdfDownload PDFimage_print

November 28, 2017

Audience: Laboratory, Health Professional, Patient

ISSUE: The FDA is alerting the public, health care providers, lab personnel, and lab test developers that biotin can significantly interfere with certain lab tests and cause incorrect test results which may go undetected.

Biotin in blood or other samples taken from patients who are ingesting high levels of biotin in dietary supplements can cause clinically significant incorrect lab test results. The FDA has seen an increase in the number of reported adverse events, including one death, related to biotin interference with lab tests.

Biotin in patient samples can cause falsely high or falsely low results, depending on the test. Incorrect test results may lead to inappropriate patient management or misdiagnosis. For example, a falsely low result for troponin, a clinically important biomarker to aid in the diagnosis of heart attacks, may lead to a missed diagnosis and potentially serious clinical implications. The FDA has received a report that one patient taking high levels of biotin died following falsely low troponin test results when a troponin test known to have biotin interference was used.

The FDA is aware of people taking high levels of biotin that would interfere with lab tests. Many dietary supplements promoted for hair, skin, and nail benefits contain biotin levels up to 650 times the recommended daily intake of biotin. Physicians may also be recommending high levels of biotin for patients with certain conditions such as multiple sclerosis (MS). Biotin levels higher than the recommended daily allowance may cause interference with lab tests.

Patients and physicians may be unaware of biotin interference in laboratory assays. Even physicians who are aware of this interference are likely unaware as to whether, and how much biotin, patients are taking. Since patients are unaware of biotin interference, patients may not report taking biotin supplements to their physicians, and may even be unware they are taking biotin (e.g., when taking products generally labeled for their benefits to hair and nails).

The FDA is working with stakeholders to better understand biotin interference with laboratory tests, and to develop additional future recommendations for safe testing in patients who have taken high levels of biotin when using laboratory tests that use biotin technology.

The FDA is monitoring reports of adverse events associated with biotin interference with laboratory tests and will update the public if significant new information becomes available.

BACKGROUND: Many lab tests use biotin technology due to its ability to bond with specific proteins which can be measured to detect certain health conditions. For example, biotin is used in hormone tests and tests for markers of cardiac health like troponin. Biotin, also known as vitamin B7, is a water-soluble vitamin often found in multi-vitamins, prenatal vitamins, and dietary supplements marketed for hair, skin, and nail growth.

RECOMMENDATIONS:

For Health Care Providers:

  • Talk to your patients about any biotin supplements they may be taking, including supplements marketed for hair, skin, and nail growth.
  • Be aware that many lab tests, including but not limited to cardiovascular diagnostic tests and hormone tests, that use biotin technology are potentially affected, and incorrect test results may be generated if there is biotin in the patient’s specimen.
  • Communicate to the lab conducting the testing if your patient is taking biotin.
  • If a lab test result doesn’t match the clinical presentation of your patient, consider biotin interference as a possible source of error.
  • Know that biotin is found in multivitamins, including prenatal multivitamins, biotin supplements, and dietary supplements for hair, skin, and nail growth in levels that may interfere with lab tests.
  • Report to the lab test manufacturer and the FDA if you become aware of a patient experiencing an adverse event following potentially incorrect laboratory test results due to biotin interference.

For Lab Personnel:

  • If you use assays with biotin technology, be aware that it is difficult to identify samples that contain biotin; therefore, it is important to communicate with health care providers and patients to prevent incorrect test results.
  • If you are collecting samples in the lab, ask whether the patient is taking biotin.
  • Educate health care providers about biotin interference with certain lab tests used in your lab.
  • Consider that the daily recommended allowance for biotin is 0.03 mg and these biotin levels do not typically cause significant interference. However, supplements containing high biotin levels including those marketed for hair, skin, and nail benefits, may contain up to 20 mg of biotin, and physicians may recommend up to 300 mg per day for conditions such as multiple sclerosis. Biotin levels higher than the recommended daily allowance may cause significant interference with affected lab tests.
  • Be aware that specimens collected from patients taking high levels of biotin may contain more than 100 ng/mL biotin. Concentrations of biotin up to 1200 ng/mL may be present in specimens collected from patients taking up to 300 mg per day.
  • Currently available data is insufficient to support recommendations for safe testing using affected tests in patients taking high levels of biotin, including about the length of time for biotin clearance from the blood.
  • Communicate with the lab test manufacturer if you have questions about biotin interference.

For Consumers:

  • Talk to your doctor if you are currently taking biotin or are considering adding biotin, or a supplement containing biotin, to your diet.
  • Know that biotin is found in multivitamins, including prenatal multivitamins, biotin supplements, and supplements for hair, skin, and nail growth in levels that may interfere with laboratory tests.
  • Be aware that some supplements, particularly those labeled for hair, skin, and nail benefits, may have high levels of biotin, which may not be clear from the name of the supplement.
  • If you have had a lab test done and are concerned about the results, talk to your health care provider about the possibility of biotin interference.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

[11/28/2017 – Safety Communication – FDA]

Tagged with:

About author

Related Articles